Key Points
- CEO Mark Tarr sold 150,000 shares at an average price of $111.64 for about $16.75M, trimming his stake by 28.46% to 377,070 shares (worth ≈$42.10M).
- The company beat Q results, reporting $1.46 EPS vs. $1.29 expected and revenue of $3.09B (up 9.9% YoY), and set FY2026 guidance of $5.81–$6.10 EPS.
- Analysts' consensus is a Buy with an average price target of $143.29; the stock trades around $112 with a market cap of $11.29B and a PE of 20.25.
Encompass Health Corporation (NYSE:EHC - Get Free Report) CEO Mark Tarr sold 150,000 shares of the company's stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $111.64, for a total value of $16,746,000.00. Following the completion of the sale, the chief executive officer owned 377,070 shares in the company, valued at $42,096,094.80. The trade was a 28.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Encompass Health Trading Down 1.1%
Shares of NYSE:EHC opened at $112.16 on Friday. The company has a current ratio of 1.08, a quick ratio of 1.14 and a debt-to-equity ratio of 0.76. Encompass Health Corporation has a 12-month low of $92.53 and a 12-month high of $127.99. The business has a 50 day moving average of $103.98 and a two-hundred day moving average of $114.47. The company has a market capitalization of $11.29 billion, a PE ratio of 20.25, a PEG ratio of 2.16 and a beta of 0.73.
Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.29 by $0.17. Encompass Health had a net margin of 9.54% and a return on equity of 18.20%. The business had revenue of $3.09 billion for the quarter, compared to analysts' expectations of $1.54 billion. During the same quarter last year, the company earned $1.17 EPS. The business's revenue was up 9.9% on a year-over-year basis. Encompass Health has set its FY 2026 guidance at 5.810-6.100 EPS. As a group, analysts forecast that Encompass Health Corporation will post 4.8 EPS for the current year.
Wall Street Analysts Forecast Growth
EHC has been the topic of a number of analyst reports. Zacks Research cut Encompass Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, November 19th. Raymond James Financial upgraded Encompass Health to a "strong-buy" rating in a research report on Friday, October 31st. Barclays increased their target price on Encompass Health from $150.00 to $153.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Finally, Wall Street Zen raised shares of Encompass Health from a "hold" rating to a "buy" rating in a report on Sunday, January 18th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $143.29.
Check Out Our Latest Research Report on EHC
Institutional Trading of Encompass Health
Institutional investors have recently made changes to their positions in the company. Tectonic Advisors LLC raised its stake in Encompass Health by 1.6% in the 3rd quarter. Tectonic Advisors LLC now owns 5,337 shares of the company's stock valued at $678,000 after purchasing an additional 82 shares during the last quarter. Global Retirement Partners LLC raised its position in shares of Encompass Health by 23.0% in the third quarter. Global Retirement Partners LLC now owns 449 shares of the company's stock valued at $57,000 after buying an additional 84 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Encompass Health by 2.4% in the second quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company's stock worth $453,000 after buying an additional 88 shares in the last quarter. Natural Investments LLC boosted its position in Encompass Health by 1.2% during the third quarter. Natural Investments LLC now owns 7,808 shares of the company's stock worth $991,000 after acquiring an additional 89 shares during the last quarter. Finally, Allworth Financial LP grew its stake in Encompass Health by 14.7% during the 3rd quarter. Allworth Financial LP now owns 701 shares of the company's stock valued at $89,000 after acquiring an additional 90 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.
About Encompass Health
(
Get Free Report)
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
